Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 6/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.37 |
| ▸ | NPY1R | P25929 | 5/20 | 0.37 |
| ▸ | NPY2R | P49146 | 3/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
| ▸ | NMT2 | O60551 | 1/20 | 0.37 |
| ▸ | NMT1 | P30419 | 1/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
| ▸ | TFPI | P10646 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GNPAT | O15228 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12999807 | 0.92 | NPY4R (0.40) | NPY4RNPY5RNPY1RNPY2RNMT2 | |
| SCHEMBL16358960 | 0.88 | TLR2 (0.45) | NPY4RNPY5RNPY1RNPY2RTLR2 | |
| SCHEMBL10169928 | 0.87 | OPRL1 (0.40) | NPY4RNPY5RNPY1RNPY2RTLR2 | |
| SCHEMBL16329426 | 0.86 | TLR2 (0.43) | NPY4RNPY5RNPY1RNPY2RTLR2 | |
| SCHEMBL29536066 | 0.85 | GNPAT (0.50) | NPY4RNPY5RNPY1RNPY2RNMT2 | |
| SCHEMBL14193566 | 0.85 | GNPAT (0.40) | NPY4RNPY5RNPY1RNPY2RNMT2 | |
| SCHEMBL13319653 | 0.84 | QRFPR (0.42) | NPY4RNPY5RNPY1RNPY2RTLR2 | |
| SCHEMBL17440322 | 0.84 | QRFPR (0.42) | NPY4RNPY5RNPY1RNPY2RTLR2 | |
| SCHEMBL5849470 | 0.84 | OPRL1 (0.40) | NPY4RNPY5RNPY1RNPY2RCXCR4 | |
| SCHEMBL5849482 | 0.84 | OPRL1 (0.40) | NPY4RNPY5RNPY1RNPY2RCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760762-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20170334925-A1 | Thienopyranones as Kinase and Epigenetic Inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170101418-A1 | Thienopyranones as Kinase and Epigenetic Inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2017-04-13 | — | — | US | disclosed |
| US-20170101419-A1 | Thienopyranones as Kinase Inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2017-04-13 | — | — | US | disclosed |
| US-9550790-B2 | Thienopyranones as kinase inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9505780-B2 | Thienopyranones as kinase and epigenetic inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150344494-A1 | Thienopyranones as Kinase and Epigenetic Inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20140073584-A1 | Thienopyranones as Kinase Inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8557807-B2 | Thienopyranones as kinase inhibitors | Signal Rx Pharmaceuticals, Inc. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20100310466-A1 | THIENOPYRANONES AS KINASE INHIBITORS | SIGNALRX PHARMACEUTICALS, INC. | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310466-A1 | THIENOPYRANONES AS KINASE INHIBITORS | MAP3K3, MAP3K6, MAP3K1 | NPY4R 4741/4885NPY5R 4808/4885NPY1R 4752/4885 |
| US-11760762-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | CDK1, CDKN1A, CDKL1 | NPY4R 4052/4885NPY5R 4530/4885NPY1R 3066/4885 |
| US-20170101418-A1 | Thienopyranones as Kinase and Epigenetic Inhibitors | MYC, BRD4, MKNK1 | NPY4R 4183/4885NPY5R 4571/4885NPY1R 3406/4885 |
| US-20140073584-A1 | Thienopyranones as Kinase Inhibitors | MAP3K3, MAP3K6, MAP3K1 | NPY4R 4721/4885NPY5R 4788/4885NPY1R 4740/4885 |
| US-20170101419-A1 | Thienopyranones as Kinase Inhibitors | MAP3K3, MAP3K6, MAP3K1 | NPY4R 4721/4885NPY5R 4788/4885NPY1R 4740/4885 |
| US-20170334925-A1 | Thienopyranones as Kinase and Epigenetic Inhibitors | MYC, BRD4, MYCBP | NPY4R 4187/4885NPY5R 4725/4885NPY1R 3773/4885 |
| US-20150344494-A1 | Thienopyranones as Kinase and Epigenetic Inhibitors | MYC, BRD4, MKNK1 | NPY4R 3971/4885NPY5R 4678/4885NPY1R 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.